Heart, Lung and Circulation
Original Article| Volume 27, ISSUE 6, P656-665, June 2018

Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial


      Simvastatin plus ezetimibe reduced the risk of cardiovascular events in the IMProved Reduction of Outcomes: Vytorin Efficacy International (IMPROVE-IT) study. The aim of this study is to investigate the cost-effectiveness of adding ezetimibe to simvastatin treatment for patients with ACS based on the recently completed IMPROVE-IT trial.


      We constructed a Markov state-transition model to evaluate the costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness (ICER) associated with co-therapy compared with simvastatin alone from a health care perspective. We ran separate base-case analyses assuming a trial-length and longer term follow-up. One-way sensitivity analyses were used to explore uncertainty in model parameters.


      In the trial-length model, the ICERs compared with simvastatin alone were $114,400 per QALY for the combination therapy. In 5- and 10-year time horizons, the ICERs remained above the cost-effectiveness threshold of $50,000 per QALY. In the lifetime horizon model, The ICER was $45,046 per QALY for combination treatment compared with simvastatin alone. The combination therapy is cost-effective at an 80% decrease in the current branded simvastatin and ezetimibe cost. Probabilistic sensitivity analysis suggested simvastatin and ezetimibe co-therapy would be a cost-effective alternative to simvastatin monotherapy 60.7% of the time.


      In our trial-length, 5-year, and 10-year models, the co-therapy was not a cost-effective alternative; however, as follow-up was extended to lifetime, the co-therapy became a cost-effective treatment compared with the simvastatin monotherapy in patients with histories of ACS.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Heart, Lung and Circulation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Go A.S.
        • Mozaffarian D.
        • Roger V.L.
        • Benjamin E.J.
        • Berry J.D.
        • Blaha M.J.
        • et al.
        Heart disease and stroke statistics?2014 update: a report from the American Heart Association.
        Circulation. 2014; 129: e28-292
      1. Centers for Disease Control and Prevention, National Center for Health Statistics. 2012 National Ambulatory Medical Care Survey and 2012 National Hospital Ambulatory Medical Care Survey. Accessed February 2, 2013.

        • Trogdon J.G.
        • Finkelstein E.A.
        • Nwaise I.A.
        • Tangka F.K.
        • Orenstein D.
        The economic burden of chronic cardiovascular disease for major insurers.
        Health Promot Pract. 2007; 8: 234-242
        • Kolansky D.M.
        Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden.
        Am J Manag Care. 2009; 15: S36-S41
        • Turpie A.G.
        Burden of disease: medical and economic impact of acute coronary syndromes.
        Am J Manag Care. 2006; 12: S430-S434
        • Grech E.D.
        • Ramsdale D.R.
        Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction.
        BMJ. 2003; 326: 1259-1261
        • Go A.S.
        • Mozaffarian D.
        • Roger V.L.
        • Benjamin E.J.
        • Berry J.D.
        • Blaha M.J.
        • et al.
        Heart disease and stroke statistics?2014 update: a report from the American Heart Association.
        Circulation. 2014; 129: e28-292
        • National Institutes of Health
        Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
        NIH 02-5215, Washington, DC2002
      2. Carroll MD, Kit BK, Lacher DA. Total and high-density lipoprotein cholesterol in adults: National Health and Nutrition Examination Survey, 2009–2010. NCHS data brief, no 92. http://nchs/data/databriefs/db92.pdf.

        • Heidenreich P.A.
        • Trogdon J.G.
        • Khavjou O.A.
        • Butler J.
        • Dracup K.
        • Ezekowitz M.D.
        • et al.
        Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association.
        Circulation. 2011; 123: 933-944
        • Stone N.J.
        • Robinson J.G.
        • Lichtenstein A.H.
        • Merz C.N.B.
        • Blum C.B.
        • Eckel R.H.
        • et al.
        2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2014; 129: S1-45
        • Altmann S.W.
        • Davis H.R.
        • Zhu L.J.
        • Yao X.
        • Hoos L.M.
        • Tetzloff G.
        • et al.
        Niemann-Pick C1 like1 protein is critical for intestinal cholesterol absorption.
        Science. 2004; 303: 1201-1204
        • Ballantyne C.M.
        • Houri J.
        • Notarbartolo A.
        • Melani L.
        • Lipka L.J.
        • Suresh R.
        • et al.
        Effect of ezetimibe co-administered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
        Circulation. 2003; 107: 2409-2415
        • Davidson M.H.
        • McGarry T.
        • Bettis R.
        • Melani L.
        • Lipka L.J.
        • LeBeaut A.P.
        • et al.
        Ezetimibe co-administered with simvastatin in patients with primary hypercholesterolemia.
        J Am Coll Cardiol. 2002; 40: 2125-2134
        • Gagné C.
        • Bays H.E.
        • Weiss S.R.
        • Mata P.
        • Quinto K.
        • Melino M.
        • et al.
        Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.
        Am J Cardiol. 2002; 90: 1084-1091
        • Ginsberg H.N.
        • Elam M.B.
        • Lovato L.C.
        • Crouse 3rd, J.R.
        • Leiter L.A.
        • Linz P.
        • et al.
        ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
        N Engl J Med. 2010; 362: 1563-1574
        • Thongtang N.
        • Lin J.
        • Schaefer E.J.
        • Lowe R.S.
        • Tomassini J.E.
        • Shah A.K.
        • et al.
        Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients.
        Atherosclerosis. 2012; 2: 388-396
        • Gudzune K.A.
        • Monroe A.K.
        • Sharma R.
        • Ranasinghe P.D.
        • Chelladurai Y.
        • Robinson K.A.
        Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review.
        Ann Intern Med. 2014; 160: 468-476
        • Lorenz M.W.
        • Markus H.S.
        • Bots M.L.
        • Rosvall M.
        • Sitzer M.
        Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and metaanalysis.
        Circulation. 2007; 115: 459-467
        • Cannon C.P.
        • Blazing M.A.
        • Giugliano R.P.
        • McCagg A.
        • White J.A.
        • Theroux P.
        • et al.
        Ezetimibe added to statin therapy after acute coronary syndromes.
        N Engl J Med. 2015; 372: 2387-2397
        • Bissonnette S.
        • Habib R.
        • Sampalis F.
        • Boukas S.
        • Sampalis J.S.
        Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study–the Ezetrol Add-On Study.
        Can J Cardiol. 2006; 22: 1035-1044
        • Weinstein M.C.
        • Siegel J.E.
        • Gold M.R.
        • Kamlet M.S.
        • Russell L.B.
        Recommendations of the panel on cost-effectiveness in health and medicine.
        JAMA. 1996; 276: 1253-1258
        • Miller D.K.
        • Homan S.M.
        Determining transition probabilities: confusion and suggestions.
        Med Decis Making. 1994; 14: 52-58
      3. National Center for Health Statistics: United States life tables, 2011. Accessed December 15, 2015.

        • Russell L.B.
        • Gold M.R.
        • Siegel J.E.
        • Daniels N.
        • Weinstein M.C.
        The role of cost effectiveness analysis in health and medicine.
        JAMA. 1996; 276: 1172-1177
        • Agency for Healthcare Research and Quality
        HCUPnet: A tool for identifying, tracking, and analyzing national hospital statistics.
        2009 (Retrieved 1/11, 2016, from
        • Finkler S.A.
        The distinction between cost and charges.
        Ann Intern Med. 1982; 96: 102-109
        • Finklestein E.A.
        • Corso P.S.
        The Incidence and Economic Burden of Injuries in the United States.
        Oxford University Press, New York2006 (Associates MTa)
        • Shah S.V.
        • Gage B.F.
        Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
        Circulation. 2011; 123: 2562-2570
      4. Accessed February 3, 2016.

        • King D.R.
        • Kanavos P.
        Encouraging the use of generic medicines: implications for transition economies.
        Croat Med J. 2002; 43: 462-469
        • Steg P.G.
        • Kerner A.
        • Van de Werf F.
        • López-Sendón J.
        • Gore J.M.
        • FitzGerald G.
        • et al.
        Impact of in-hospital revascularization on survival in patients with non?ST-elevation acute coronary syndrome and congestive heart failure.
        Circulation. 2008; 118: 1163-1171
        • Cannon C.P.
        • McCabe C.H.
        • Stone P.H.
        • Rogers W.J.
        • Schactman M.
        • Thompson B.W.
        • et al.
        The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia.
        J Am Coll Cardiol. 1997; 30: 133-140
        • Davies E.W.
        • Matza L.S.
        • Worth G.
        • Feeny D.H.
        • Kostelec J.
        • Soroka S.
        • et al.
        Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis.
        Health Qual Life Outcomes. 2015; 13: 90
        • Kamel H.
        • Johnston S.C.
        • Easton J.D.
        • Kim A.S.
        Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
        Stroke. 2012; 43: 881-883
        • Kalish S.C.
        • Gurwitz J.H.
        • Krumholz H.M.
        • Avorn J.
        A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.
        J Gen Intern Med. 1995; 10: 321-330
        • Braithwaite R.S.
        • Meltzer D.O.
        • King Jr., J.T.
        • Leslie D.
        • Roberts M.S.
        What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?.
        Med Care. 2008; 46: 349-356
        • Laupacis A.
        • Feeny D.
        • Detsky A.S.
        • Tugwell P.X.
        How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.
        CMAJ. 1992; 146: 473-481
        • Weinstein M.C.
        From cost-effectiveness ratios to resource allocation: where to draw the line?.
        in: Sloan F.A. Valuing Health Care: Costs, Benefits, and Effectiveness of Pharmaceuticals and Other Medical Technologies. Cambridge University Press, New York1995
        • Hirth R.A.
        • Chernew M.E.
        • Miller E.
        • Fendrick A.M.
        • Weissert W.G.
        Willingness to pay for a quality-adjusted life year: in search of a standard.
        Med Decis Making. 2000; 20: 332-342
        • Briggs A.H.
        • O’Brien B.J.
        • Blackhouse G.
        Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies.
        Annu Rev Public Health. 2002; 23: 377-401
        • Caro J.J.
        • Briggs A.H.
        • Siebert U.
        • Kuntz K.M.
        Modeling good research practices—overview a report of the ISPOR-SMDM modeling good research practices task force-1.
        Med Decis Making. 2012; 32: 667-677
        • Lloyd-Jones D.M.
        • Morris P.B.
        • Ballantyne C.M.
        • Birtcher K.K.
        • Daly D.D.
        • DePalma S.M.
        • et al.
        2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.
        J Am Coll Cardiol. 2016; (Mar 28)
        • Ara R.
        • Pandor A.
        • Tumur I.
        • Paisley S.
        • Duenas A.
        • Williams R.
        • et al.
        Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.
        Clin Ther. 2008; 30: 1508-1523
        • van Nooten F.
        • Davies G.M.
        • Jukema J.W.
        • Liem A.H.
        • Yap E.
        • Hu X.H.
        Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia.
        Neth Heart J. 2011; 19: 61-67
        • Reckless J.
        • Davies G.
        • Tunceli K.
        • Hu X.H.
        • Brudi P.
        Projected cost effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study.
        Value Health. 2010; 13: 726-734
        • Insull Jr, W.
        Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review.
        South Med J. 2006; 99: 257-273
        • Aldridge M.A.
        • Ito M.K.
        Colesevelam hydrochloride: a novel bile acid-binding resin.
        Ann Pharmacother. 2001; 35: 898-907
        • Hunninghake D.B.
        • Bell C.
        • Olson L.
        Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia.
        Metabolism. 1981; 30: 610-615
        • Insull W.
        • Davidson M.H.
        • Demke D.M.
        • Dujovne C.A.
        • Eckert S.M.
        • Ginsberg D.
        • et al.
        The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients.
        Atherosclerosis. 1995; 112: 223-235
        • Vecchio T.J.
        • Linden C.V.
        • O’Connell M.J.
        • Heilman J.
        Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia.
        Arch Intern Med. 1982; 142: 721-723
        • Staels B.
        • Dallongeville J.
        • Auwerx J.
        • Schoonjans K.
        • Leitersdorf E.
        • Fruchart J.C.
        Mechanism of action of fibrates on lipid and lipoprotein metabolism.
        Circulation. 1998; 98: 2088-2093
        • Wierzbicki A.S.
        • Mikhailidis D.P.
        • Wray R.
        • Schachter M.
        • Cramb R.
        • Simpson W.G.
        • et al.
        Statin-fibrate combination therapy for hyperlipidaemia: a review.
        Curr Med Res Opin. 2003; 19: 155-168
        • Knopp R.H.
        • Davidson M.
        • Goldberg A.C.
        • Kafonek S.D.
        • Kashyap M.
        • Sprecher D.
        • et al.
        Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
        Metabolism. 1998; 47: 1097-1104
        • Blankenhorn D.H.
        • Selzer R.H.
        • Crawford D.W.
        • Barth J.D.
        • Liu C.R.
        • Liu C.H.
        • et al.
        Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two-and four-year reduction of intima-media thickness measured by ultrasound.
        Circulation. 1993; 88: 20-28